ERBB2 and neoplasm: We also leveraged this prospective tumor sequencing initiative to develop and biologically characterize novel ERBB2 amplified and mutant urothelial cancer patient-derived organoid and xenograft models that better reflect the genomic and biologic complexity of urothelial cancers than older 2D cell line models.